metastatic digestive system tumors
Conditions
Interventions
Experimental group:a CDK4 / 6 inhibitor and a MEK inhibitor
Sponsors
Henan Cancer Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1) Aged 18-75 years; 2) ECOG score <= 1; 3) Patients with advanced KRAS mutation or metastatic digestive system tumor confirmed by histology or cytology and imaging diagnosis; 4) According to recist1.1, there was at least one measurable lesion; 5) The expected survival time was more than 12 weeks.
Exclusion criteria
Exclusion criteria: 1) Patients who received any anti-tumor treatment within 4 weeks before enrollment, including radiotherapy, chemotherapy, molecular targeted therapy and immunotherapy, or participated in another intervention clinical trial; 2) Previous treatment with targeted BRAF, MEK, ERK or CDK family related inhibitors; 3) The third space effusion (such as massive pleural effusion or ascites) with clinical symptoms that cannot be controlled by drainage or other methods; 4) Allergy to any test drug and its excipients, or serious allergic history, or contraindication of the test drug; 5) Have a history of immunodeficiency, including HIV positive, or other acquired, congenital immunodeficiency diseases, or a history of organ transplantation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective remission rate; | — |
Countries
China
Contacts
Public ContactSuxia Luo, Li Ning
Henan Cancer Hospital
Outcome results
None listed